Skip to content Skip to footer
Subscribe Now
VIEWPOINTS

Navigating Amorphous Calcium Carbonate Therapies: Eden Ben from Amorphical in Conversation with PharmaShots 

Shots: ACC therapies introduce a novel treatment approach by modulating local pH, promoting bone remodeling, and reducing inflammation, with potential applications in osteoarthritis, calcium deficiencies, late-stage cancers, and bone disorders. Amorphical’s AMOR-18 showed encouraging results in an interim Phase II clinical trial involving COVID-19 patients. PharmaShots speaks with Eden Ben, CEO of Amorphical, to discuss…
September 22, 2025

Read more

VIEWPOINTS

Pain Management & Beyond: Paul Howe from Protega Pharmaceuticals in a Stimulating Conversation with PharmaShots 

Shots: Abuse-deterrent products are prescription medications, primarily opioids and certain stimulants, designed to resist common methods of misuse, such as crushing, snorting, or injecting Protega Pharmaceuticals’ RoxyBond is the first and only FDA-approved, immediate-release abuse-deterrent opioid indicated for managing severe pain when alternative treatments are inadequate PharmaShots is pleased to feature Paul Howe, Chief Operations…
September 17, 2025

Read more

Mehul Desai from Enable Injections in a Riveting Conversation with PharmaShots
VIEWPOINTS

Wearable Drug Delivery System: Mehul Desai from Enable Injections in a Riveting Conversation with PharmaShots 

Shots: Enable Injections recently shared survey findings indicating that many oncology assets with strong commercial potential are often prematurely abandoned or deprioritized due to challenges in formulating small volumes (<3 mL) for subcutaneous delivery. To address this need, Enable Injections developed enFuse, an innovative, hands-free, wearable drug delivery platform with a discreet, hidden needle that…
September 15, 2025

Read more

Rick Modi from Affinia Therapeutics in a Stirring Dialogue Exchange with PharmaShots
SPOTLIGHT

CXO Talks: Rick Modi from Affinia Therapeutics in a Stirring Dialogue Exchange with PharmaShots

Shots:In this episode of the CXO Talks podcast, PharmaShots speaks with Rick Modi, CEO at Affinia TherapeuticsDriven by cutting-edge innovation, Affinia is pioneering and re-imagining adeno-associated virus serotype 9 (AAV9), a gene therapy delivery method for conditions affecting cardiac muscle, skeletal muscle, and the central nervous systemRick articulates the diagnostic and therapeutic…
September 8, 2025

Read more

Joshua Salsi from Biocon Biologics in a Riveting Conversation with PharmaShots
VIEWPOINTS

Unlocking Approval: Joshua Salsi from Biocon Biologics in a Riveting Conversation with PharmaShots 

Shots: The United States has about 38.4 million people living with diabetes, representing 11.6% of the total population. With growing prevalence, there is a significant unmet need for affordable diabetes medications. Biocon Biologics recently announced the FDA approval of Kirsty, the first and only interchangeable biosimilar to NovoLog (Insulin Aspart). Joshua Salsi, the Head of…
September 8, 2025

Read more

Shawn Opatka from Honeywell in a Riveting Dialogue Exchange with PharmaShots
VIEWPOINTS

AI-Mediated Recalls: Shawn Opatka from Honeywell in a Riveting Dialogue Exchange with PharmaShots

Shots: Product recalls in biopharma and MedTech incur an unanticipated drain on budget, costing the industry between $2.5B to $5B per year on average Honeywell’s TrackWise Recall Management helps biopharma and MedTech companies plan and execute recall processes seamlessly, contributing to improved patient safety and faster response times Shawn Opatka, Vice President & General Manager,…
September 1, 2025

Read more

Jazz Pharmaceuticals at ASCO 2025: Robert lannone in an Illuminating Conversation with PharmaShots
VIEWPOINTS

Jazz Pharmaceuticals at ASCO 2025: Robert lannone in an Illuminating Conversation with PharmaShots

Shots: Jazz Pharmaceuticals and partners presented seven abstracts from their oncology development program at ASCO 2025  Robert Iannone, EVP, Global Head of Research and Development, and Chief Medical Officer at Jazz Pharmaceuticals, in an engaging discussion with PharmaShots, shared insights from the P-III IMforte trial assessing Zepzelca plus atezolizumab in first-line maintenance treatment for Extensive…
August 25, 2025

Read more

Roadblocks to Specialty Medicines Access: Colin Banas from DrFirst in Conversation with PharmaShots
VIEWPOINTS

Roadblocks to Specialty Medicines Access: Colin Banas from DrFirst in Conversation with PharmaShots 

Shots: Fragmented workflows continue to be a major roadblock in the healthcare ecosystem, causing unnecessary delays in care delivery Automated solutions help bridge the gaps resulting from disjointed workflows and expedite prior authorization, pharmacy routing, and patient onboarding Colin Banas, CMO at DrFirst, joins PharmaShots in a discussion highlighting the company’s recent acquisition of Myndshft…
August 20, 2025

Read more

Load more